Hypertrophic Cardiomyopathy (HCM) Update for Pharmacists in 2026

Join us for a deep dive into hypertrophic cardiomyopathy (HCM) with Andrew Williford, PharmD, an assistant professor and cardiology specialist at UC San Diego Health. In this episode, we break down the genetics, diagnosis, and clinical impact of HCM, explore how management strategies have evolved, and discuss the emerging role of cardiac myosin inhibitors in treating obstructive disease. Dr. Williford also shares insights from his telehealth GDMT titration clinic and offers practical guidance for pharmacists encountering HCM across care settings. Show notes: Hypertrophic Cardiomyopathy Guideline Hub Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial